CSL (CSL.AX) Stock Price

CSL Price

🇦🇺ASX·CLOSED
100.37USD
Market closed
Today +/-
-0.83 USD
Today %
-0.82 %

CSL (CSL.AX) Stock | ISIN AU000000CSL8 | WKN 890952. The current CSL stock price is 100.37 USD (2026). Revenue is 16 B USD. Net income is 3.4 B USD. The P/E ratio is 14.34. Market capitalization is 48.8 B USD. CSL operates in the Health sector.

CSL stock price

Ex-Dividend
Details

Stock Price

How to Read This Chart

This chart tracks the historical stock price of CSL over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how CSL stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing CSL's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

CSL Stock Price History
DateCSL Price
3/27/2026100.37 USD
3/26/2026101.19 USD
3/25/202698.78 USD
3/24/202697.77 USD
3/23/202698.21 USD
3/20/202696.78 USD
3/19/202694.43 USD
3/18/202697.04 USD
3/17/202699.13 USD
3/16/202698.62 USD
3/13/202698.87 USD
3/12/202699.01 USD
3/11/202699.94 USD
3/10/2026101.05 USD
3/9/202699.4 USD
3/6/2026102.36 USD
3/5/2026102.88 USD
3/4/2026100.11 USD
3/3/2026101.71 USD
3/2/2026103.25 USD
2/27/2026102.81 USD
2/26/2026102.36 USD
2/25/2026101.64 USD
2/24/2026101.76 USD
2/23/2026103.55 USD
2/20/2026107.74 USD
2/19/2026108.03 USD
2/18/2026107.01 USD
2/17/2026106.17 USD
2/16/2026106.63 USD
2/13/2026105.23 USD
2/12/2026107.68 USD
2/11/2026113.53 USD
2/10/2026128.69 USD
2/9/2026126.43 USD
2/6/2026126.43 USD
2/5/2026127.32 USD
2/4/2026127.38 USD
2/3/2026124.84 USD
2/2/2026124.42 USD
1/30/2026127.94 USD
1/29/2026125.96 USD
1/28/2026125.91 USD
1/27/2026128.35 USD
1/23/2026126.15 USD
1/22/2026124.9 USD
1/21/2026123.25 USD
1/20/2026124.02 USD
1/19/2026123.7 USD
1/16/2026123.2 USD
1/15/2026122.87 USD
1/14/2026121.51 USD
1/13/2026121.68 USD
1/12/2026122.73 USD
1/9/2026122 USD
1/8/2026122.29 USD
1/7/2026119.16 USD
1/6/2026118.59 USD
1/5/2026120.98 USD
1/2/2026120.53 USD
12/31/2025121.24 USD
12/30/2025120.81 USD
12/29/2025121.77 USD
12/24/2025120.58 USD
12/23/2025123.41 USD
12/22/2025123.93 USD
12/19/2025122.86 USD
12/18/2025122.33 USD
12/17/2025121.44 USD
12/16/2025124.52 USD
12/15/2025126.12 USD
12/12/2025128.96 USD
12/11/2025125.02 USD
12/10/2025127.13 USD
12/9/2025128.18 USD
12/8/2025130.28 USD
12/5/2025128.73 USD
12/4/2025129.88 USD
12/3/2025127.78 USD
12/2/2025128.19 USD
12/1/2025128.09 USD
11/28/2025130.37 USD
11/27/2025130.38 USD
11/26/2025128.08 USD
11/25/2025127.51 USD
11/24/2025128.59 USD
11/21/2025125.59 USD
11/20/2025125.24 USD
11/19/2025125.52 USD
11/18/2025126.22 USD
11/17/2025126.86 USD
11/14/2025127.85 USD
11/13/2025126.9 USD
11/12/2025125.89 USD
11/11/2025125.18 USD
11/10/2025125.25 USD
11/7/2025125.49 USD
11/6/2025125.74 USD
11/5/2025123.03 USD
11/4/2025123.43 USD
11/3/2025122.94 USD
10/31/2025125.55 USD
10/30/2025126.01 USD
10/29/2025119.91 USD
10/28/2025125.56 USD
10/27/2025148.14 USD
10/24/2025149.5 USD
10/23/2025152.49 USD
10/22/2025154.9 USD
10/21/2025154.15 USD
10/20/2025152.84 USD
10/17/2025153.34 USD
10/16/2025154.76 USD
10/15/2025151.6 USD
10/14/2025147.98 USD
10/13/2025146.21 USD
10/10/2025146.85 USD
10/9/2025145.27 USD
10/8/2025144.44 USD
10/7/2025143.55 USD
10/6/2025143.64 USD
10/3/2025145.39 USD
10/2/2025144.73 USD
10/1/2025139.51 USD
9/30/2025138.79 USD
9/29/2025139.9 USD
9/26/2025136.14 USD
9/25/2025138.7 USD
9/24/2025138.28 USD
9/23/2025139.98 USD
9/22/2025139.86 USD
9/19/2025139.04 USD
9/18/2025139.76 USD
9/17/2025140.64 USD
9/16/2025141.2 USD
9/15/2025142.94 USD
9/12/2025145.98 USD
9/11/2025143.66 USD
9/10/2025148.19 USD
9/9/2025146.56 USD
9/8/2025149.78 USD
9/5/2025147.07 USD
9/4/2025147.08 USD
9/3/2025144.83 USD
9/2/2025145.61 USD
9/1/2025147.66 USD
8/29/2025149.03 USD
8/28/2025149.29 USD
8/27/2025151.1 USD
8/26/2025150.81 USD
8/25/2025151.51 USD
8/22/2025153.15 USD
8/21/2025158.14 USD
8/20/2025155.25 USD
8/19/2025159.67 USD
8/18/2025190.18 USD
8/15/2025189.22 USD
8/14/2025189.6 USD
8/13/2025188.96 USD
8/12/2025185.01 USD
8/11/2025184.61 USD
8/8/2025183.07 USD
8/7/2025186.28 USD
8/6/2025189.1 USD
8/5/2025187.75 USD
8/4/2025185.9 USD
8/1/2025184.96 USD
7/31/2025191.48 USD
7/30/2025190.44 USD
7/29/2025190.67 USD
7/28/2025190.11 USD
7/25/2025188.31 USD
7/24/2025189.21 USD
7/23/2025186.28 USD
7/22/2025185.21 USD
7/21/2025179.28 USD
7/18/2025180.41 USD
7/17/2025173.81 USD
7/16/2025173.67 USD
7/15/2025175.73 USD
7/14/2025169.45 USD
7/11/2025168.58 USD
7/10/2025169.38 USD
7/9/2025170.58 USD
7/8/2025172.7 USD
7/7/2025173.82 USD
7/4/2025170.29 USD
7/3/2025169.65 USD
7/2/2025168.39 USD
7/1/2025167.28 USD
6/30/2025168.37 USD
6/27/2025164.76 USD
6/26/2025168.55 USD
6/25/2025167.56 USD
6/24/2025168.81 USD
6/23/2025168.52 USD
6/20/2025168.47 USD
6/19/2025167.44 USD
6/18/2025169.44 USD
6/17/2025167.45 USD
6/16/2025167.45 USD
6/13/2025166.94 USD
6/12/2025169.05 USD
6/11/2025169.14 USD
6/10/2025170.82 USD
6/6/2025169.59 USD
6/5/2025170.12 USD
6/4/2025172.53 USD
6/3/2025171.97 USD
6/2/2025173.57 USD
5/30/2025173.58 USD
5/29/2025173.6 USD
5/28/2025173.22 USD
5/27/2025174.6 USD
5/26/2025173.25 USD
5/23/2025172.52 USD
5/22/2025173.13 USD
5/21/2025171.36 USD
5/20/2025171.83 USD
5/19/2025169.89 USD
5/16/2025169.88 USD
5/15/2025167.67 USD
5/14/2025167.95 USD
5/13/2025168.46 USD
5/12/2025164.91 USD
5/9/2025167.63 USD
5/8/2025168.06 USD
5/7/2025170.81 USD
5/6/2025175.21 USD
5/5/2025180.45 USD
5/2/2025179.73 USD
5/1/2025176.75 USD
4/30/2025175.23 USD
4/29/2025171.88 USD
4/28/2025171.63 USD
4/24/2025168.7 USD
4/23/2025167.95 USD
4/22/2025165.9 USD
4/17/2025168.02 USD
4/16/2025169.82 USD
4/15/2025170.83 USD
4/14/2025166.8 USD
4/11/2025163.65 USD
4/10/2025168.81 USD
4/9/2025163.56 USD
4/8/2025172.08 USD
4/7/2025170.4 USD
4/4/2025179.75 USD
4/3/2025180.23 USD
4/2/2025179.17 USD
4/1/2025175.71 USD
3/31/2025174.9 USD
Access this data via the Eulerpool API

CSL Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2006
2.17 B USD
158.4 M USD
87.7 M USD
Jan 1, 2007
2.6 B USD
643 M USD
423.3 M USD
Jan 1, 2008
3.4 B USD
896.3 M USD
627.9 M USD
Jan 1, 2009
3.69 B USD
1.05 B USD
842.2 M USD
Jan 1, 2010
4.06 B USD
1.23 B USD
926.7 M USD
Jan 1, 2011
4.26 B USD
1.2 B USD
936.5 M USD
Jan 1, 2012
4.77 B USD
1.3 B USD
1.01 B USD
Jan 1, 2013
5.13 B USD
1.52 B USD
1.22 B USD
Jan 1, 2014
5.52 B USD
1.66 B USD
1.31 B USD
Jan 1, 2015
5.63 B USD
1.77 B USD
1.38 B USD
Jan 1, 2016
6.12 B USD
1.44 B USD
1.24 B USD
Jan 1, 2017
6.92 B USD
1.77 B USD
1.34 B USD
Jan 1, 2018
7.92 B USD
2.38 B USD
1.73 B USD
Jan 1, 2019
8.54 B USD
2.5 B USD
1.92 B USD
Jan 1, 2020
9.15 B USD
2.72 B USD
2.1 B USD
Access this data via the Eulerpool API

CSL Income Statement, Balance Sheet, Cash Flow Statement

Last updated Mar 30, 2026, 4:30 PM
 
REVENUE (B USD)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (B USD)
NET INCOME (B USD)
NET INCOME GROWTH (%)
DIV. (USD)
DIV. GROWTH (%)
SHARES (M)
DOCUMENTS
202420252026e2027e2028e2029e2030e2031e
14.815.561616.6617.4619.1220.8522.03
11.195.122.874.124.769.539.065.64
51.8351.9350.4848.4846.2842.2538.7436.68
7.678.088.088.088.088.088.088.08
2.6433.43.673.964.414.755.07
20.4213.6313.397.937.8111.447.686.61
3.64.521.34.815.2---
-3.2325.56-71.242708.11
485.2486.22486.22486.22486.22486.22486.22486.22
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales CSL generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue CSL retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare CSL's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares CSL has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against CSL's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Access this data via the Eulerpool API

CSL Stock Quarterly Figures

 
REVENUE (B USD)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (B USD)
NET INCOME (B USD)
NET INCOME GROWTH (%)
DIV. (USD)
DIV. GROWTH (%)
SHARES (M)
2024 Q42025 Q22025 Q42026 Q2e2026 Q4e2027 Q2e2027 Q4e2028 Q2e
6.758.487.088.497.68.9489.14
-16.2225.73-16.619.97-10.5217.64-10.4914.23
49.553.6249.8941.5946.4839.5144.1438.64
3.344.553.533.533.533.533.533.53
0.742.0112.021.392.251.482.5
-61.02170.85-50.42103.22-31.4562.27-34.0668.24
--------
485.41486.09486.35486.35486.35486.35486.35486.35
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales CSL generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue CSL retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare CSL's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares CSL has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against CSL's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Access this data via the Eulerpool API

CSL stock margins

The CSL margin analysis displays the gross margin, EBIT margin, as well as the profit margin of CSL. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for CSL.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2006
41.39 %
7.3 %
4.04 %
Jan 1, 2007
47.56 %
24.73 %
16.28 %
Jan 1, 2008
49.17 %
26.4 %
18.49 %
Jan 1, 2009
52.21 %
28.51 %
22.82 %
Jan 1, 2010
52.59 %
30.32 %
22.84 %
Jan 1, 2011
50.74 %
28.27 %
21.97 %
Jan 1, 2012
50.39 %
27.16 %
21.25 %
Jan 1, 2013
53.38 %
29.54 %
23.71 %
Jan 1, 2014
52.86 %
30 %
23.66 %
Jan 1, 2015
53.7 %
31.51 %
24.5 %
Jan 1, 2016
50.08 %
23.51 %
20.32 %
Jan 1, 2017
51.94 %
25.55 %
19.32 %
Jan 1, 2018
55.38 %
30.07 %
21.84 %
Jan 1, 2019
55.95 %
29.33 %
22.47 %
Jan 1, 2020
57.11 %
29.69 %
22.98 %
Access this data via the Eulerpool API

CSL Stock Revenue, EBIT, Earnings per Share

The CSL earnings per share therefore indicates how much revenue CSL has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2006
3.8 USD
0.28 USD
0.15 USD
Jan 1, 2007
4.72 USD
1.17 USD
0.77 USD
Jan 1, 2008
6.14 USD
1.62 USD
1.13 USD
Jan 1, 2009
6.17 USD
1.76 USD
1.41 USD
Jan 1, 2010
7.13 USD
2.16 USD
1.63 USD
Jan 1, 2011
7.87 USD
2.22 USD
1.73 USD
Jan 1, 2012
9.16 USD
2.49 USD
1.95 USD
Jan 1, 2013
10.25 USD
3.03 USD
2.43 USD
Jan 1, 2014
11.38 USD
3.41 USD
2.69 USD
Jan 1, 2015
11.89 USD
3.75 USD
2.91 USD
Jan 1, 2016
13.2 USD
3.1 USD
2.68 USD
Jan 1, 2017
15.17 USD
3.88 USD
2.93 USD
Jan 1, 2018
17.44 USD
5.24 USD
3.81 USD
Jan 1, 2019
18.81 USD
5.52 USD
4.23 USD
Jan 1, 2020
20.08 USD
5.96 USD
4.61 USD
Access this data via the Eulerpool API

CSL business model & stock analysis

CSL Ltd is a global leading company in the field of biological medicine, manufacturing a wide range of products used in the therapy of diseases. The company is based in Melbourne, Australia, and is one of the largest biotech companies in the country. CSL was founded in 1916 by Australian researcher Frank Macfarlane Burnet. Originally named Commonwealth Serum Laboratories, the company focused on the research and production of vaccines. CSL was then privatized in 1994 and changed its name to CSL Ltd. CSL's business model is based on the production of protein products and plasma derivatives used in immunotherapy, hematology, and transplantation medicine. The company specializes in the production and marketing of products in three main areas: plasma products, vaccines, and animal health. CSL's plasma division includes a variety of products, including intravenous immunoglobulins (IVIG), platelets, and alpha-1 antitrypsin. The company operates a number of plasma centers in the US and Europe to collect raw materials for these products. In the vaccine sector, CSL is primarily involved in the manufacture of influenza vaccines and also offers a range of other vaccines, including vaccines against snake bites and encephalitis. In the field of animal health, CSL produces animal vaccines to prevent viral infections in livestock such as pigs, poultry, and cattle. CSL is committed to research and development to develop new products and improve existing ones. The company has a long history in the research and development of vaccines and immunotherapies and has established a strong presence in this field. The company employs over 27,000 people in 35 countries worldwide and operates production facilities in Australia, the US, Europe, and Asia. CSL's headquarters are located in Parkville, a suburb of Melbourne, Australia. CSL has an impressive track record in terms of growth and profitability and is a stable market leader in its field. The company has achieved solid growth rates in recent years and generated a revenue of $8.5 billion in 2019. CSL is a key player in the global healthcare industry and has established a reputation as a reliable supplier of medical products and services. The company is committed to developing innovative solutions to advance medical progress and make a positive contribution to human health.

CSL SWOT Analysis

Strengths

CSL Ltd has a strong portfolio of life-saving products, including vaccines, gene therapies, and plasma-derived therapies. This diverse product range helps to mitigate risks and ensures a consistent revenue stream.

The company has a major competitive advantage through its strong research and development capabilities. It invests heavily in innovation and clinical trials, resulting in a continuous pipeline of new products and treatments.

Weaknesses

One of CSL Ltd's weaknesses lies in its geographical concentration of operations. With the majority of its manufacturing facilities located in Australia, the company is exposed to risks associated with regulatory changes, natural disasters, and disruptions in the supply chain.

Additionally, CSL Ltd heavily relies on plasma for its products. Any significant disruption in the plasma supply chain could impact production and lead to potential shortages.

Opportunities

The increasing demand for healthcare products and services globally provides CSL Ltd with significant growth opportunities. Expanding into emerging markets with a high demand for quality healthcare can help the company increase its market share and revenue.

The advancements in gene therapies and biotechnology open doors for CSL Ltd to develop new and innovative treatments. Partnering with academic institutions and biotechnology companies can enable the company to stay at the forefront of cutting-edge research.

Threats

CSL Ltd faces the threat of increasing competition from both established pharmaceutical companies and emerging biotech startups. This could potentially impact market share and profit margins.

The changing regulatory landscape, especially in the healthcare industry, also poses a threat to CSL Ltd. Compliance with evolving regulations and the possibility of stricter regulations can increase costs and limit operational flexibility.

Access this data via the Eulerpool API

CSL Eulerpool Fair Value

Details

Fair Value Estimate

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Access this data via the Eulerpool API

CSL historical P/E ratio, EBIT multiple, and P/S ratio

Access this data via the Eulerpool API
Access this data via the Eulerpool API

CSL shares outstanding

The number of shares was CSL in 2025 — This indicates how many shares 486.22 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2006
571.3 M base_Shares
Jan 1, 2007
551.4 M base_Shares
Jan 1, 2008
553.3 M base_Shares
Jan 1, 2009
597.7 M base_Shares
Jan 1, 2010
568.6 M base_Shares
Jan 1, 2011
541.8 M base_Shares
Jan 1, 2012
520.3 M base_Shares
Jan 1, 2013
500.3 M base_Shares
Jan 1, 2014
485.6 M base_Shares
Jan 1, 2015
473.17 M base_Shares
Jan 1, 2016
463.12 M base_Shares
Jan 1, 2017
456.37 M base_Shares
Jan 1, 2018
453.88 M base_Shares
Jan 1, 2019
454.03 M base_Shares
Jan 1, 2020
455.61 M base_Shares
Access this data via the Eulerpool API

CSL stock splits

In CSL's history, there have been no stock splits.
Access this data via the Eulerpool API

CSL Dividend History

33 years of dividend payments · 14 consecutive increases

YearAnnual DividendYoY ChangePayments
20261.3USDYTD
Mar 10, 20261.3USD 47.0%1/1
20254.52USD 13.8%
Mar 10, 20252.07USD 4.8%1/2
Sep 9, 20252.45USD 18.3%2/2
20243.97USD 7.0%
20233.72USD 14.1%
20223.26USD 8.3%
20213.01USD 2.2%
20202.94USD 10.7%
20192.66USD 16.4%
20182.28USD 30.2%
20171.75USD 3.0%
Access this data via the Eulerpool API

CSL dividend history and estimates

In 2025, CSL paid a dividend amounting to 4.52 USD. Dividend means that CSL distributes a portion of its profits to its owners.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2006
0.68 USD
0 USD
Jan 1, 2007
1.16 USD
0 USD
Jan 1, 2008
0.56 USD
0 USD
Jan 1, 2009
0.7 USD
0 USD
Jan 1, 2010
0.82 USD
0 USD
Jan 1, 2011
0.81 USD
0 USD
Jan 1, 2012
0.83 USD
0 USD
Jan 1, 2013
1.06 USD
0 USD
Jan 1, 2014
1.24 USD
0 USD
Jan 1, 2015
1.64 USD
0 USD
Jan 1, 2016
1.7 USD
0 USD
Invalid Date
1.75 USD
-0.08 USD
Jan 1, 2018
2.28 USD
0 USD
Jan 1, 2019
2.66 USD
0 USD
Jan 1, 2020
2.94 USD
0 USD
Access this data via the Eulerpool API
Access this data via the Eulerpool API

CSL dividend payout ratio

In 2025, CSL had a payout ratio of 64.54%. The payout ratio indicates the percentage of the company's profits that CSL distributes as dividends.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2006
151.07 %
Jan 1, 2007
50.12 %
Jan 1, 2008
49.43 %
Jan 1, 2009
49.65 %
Jan 1, 2010
50.38 %
Jan 1, 2011
46.73 %
Jan 1, 2012
42.56 %
Jan 1, 2013
43.47 %
Jan 1, 2014
46 %
Jan 1, 2015
56.4 %
Jan 1, 2016
63.42 %
Jan 1, 2017
59.82 %
Jan 1, 2018
59.94 %
Jan 1, 2019
62.89 %
Jan 1, 2020
63.73 %
Access this data via the Eulerpool API
Price targets and forecasts for CSL are not yet available.
Access this data via the Eulerpool API

CSL Earnings Estimates

CSL Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
2/12/20244.8USD8.2 BUSD2024 Q2
8/15/20231.93USD6.3 BUSD2023 Q4
2/14/20233.49USD7.05 BUSD2023 Q2
8/17/20221.1USD4.71 BUSD2022 Q4
2/16/20223.6USD6 BUSD2022 Q2
8/18/20211.06USD4.48 BUSD2021 Q4
2/18/20213.14USD5.7 BUSD2021 Q2
8/19/20201.95USD4.48 BUSD2020 Q4
2/12/20202.87USD4.9 BUSD2020 Q2
8/14/20191.71USD4.11 BUSD2019 Q4

EESG©

Eulerpool ESG Scorecard© for the CSL stock

89/100
75
Environment
99
Social
92
Governance
E

Environment

20
Scope 1 - Direct Emissions130,000
Scope 2 - Indirect emissions from purchased energy221,000
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions351,000
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees59
Percentage of women in management
Percentage of Asian employees5
Share of Asian management
Percentage of Hispanic/Latino employees18
Hispano/Latino Management share
Percentage of Black employees29
Black Management Share
Percentage of white employees43
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Access this data via the Eulerpool API

CSL shareholder structure

% Name
5.98682%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
4.99162%
State Street Investment Management Australia Ltd.
State Street Investment Management Australia Ltd.
2.90077%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
1.77796%
Vanguard Investments Australia Ltd.
Vanguard Investments Australia Ltd.
1.57518%
State Street Investment Management (US)
State Street Investment Management (US)
1.53251%
Norges Bank Investment Management (NBIM)
Norges Bank Investment Management (NBIM)
0.95152%
BlackRock Investment Management (Australia) Ltd.
BlackRock Investment Management (Australia) Ltd.
0.87712%
Geode Capital Management, L.L.C.
Geode Capital Management, L.L.C.
0.75144%
HUB24 Limited
HUB24 Limited
0.71872%
Colonial First State Investments Limited
Colonial First State Investments Limited
...
Access this data via the Eulerpool API

CSL Executives and Management Board

PM

Mr. Paul Mckenzie

(58)

Chief Executive Officer, Managing Director, Executive Director · since 2019

Compensation8.21 M USD
JL

Ms. Joy Linton

(58)

Chief Financial Officer

Compensation3.71 M USD
GB

Mr. Greg Boss

(62)

Executive Vice President, Legal and CSL Group General Counsel

Compensation2.5 M USD
WM

Dr. William Mezzanotte

(65)

Executive Vice President, Head Research & Development

Compensation2.16 M USD
BM

Dr. Brian Mcnamee

(67)

Non-Executive Independent Chairman of the Board

Compensation604,848 USD
Access this data via the Eulerpool API

CSL Supply Chain

CSL Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
25 companies
#Name1M3M6M1Y2YTrend
1
Terumo
Supplier
0,37
0,57
0,70
0,73
0,54
2
-0,42
-0,60
0,42
0,76
0,44
3
uniQure
Supplier
-0,15
-0,34
0,70
0,82
0,42
#Name1M3M6M1Y2YTrend
1
-0,64
-0,46
-0,74
-0,77
-0,51
2
Vifor Pharma
Supplier
0,17
0,62
-0,49
-0,77
-0,49
3
Omnicom
Supplier
-0,10
-0,26
-0,64
-0,71
-0,37
4
0,02
0,71
-0,29
-0,28
-0,23
5
-0,13
-0,39
-0,02
0,50
-0,20
Access this data via the Eulerpool API

Frequently asked questions about CSL

The business model of CSL Ltd is focused on providing innovative biotherapies and pharmaceutical products to patients worldwide. With a strong commitment to research and development, CSL specializes in developing plasma-derived and recombinant therapies for various medical conditions. The company's portfolio includes immunoglobulins, vaccines, and coagulation factors, among others. CSL operates through its two main business segments, CSL Behring and Seqirus. CSL Behring focuses on developing and manufacturing therapies for rare and serious diseases, while Seqirus is dedicated to producing influenza vaccines. CSL Ltd's business model emphasizes delivering high-quality and life-saving treatments to improve the health and well-being of individuals globally.

Access this data via the Eulerpool API

All fundamentals and in-depth analysis of CSL

Our stock analysis for CSL Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CSL Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.